The Expression Of Tumor Drug Resistance Gene ERCC-1 And RRM1 With Non-Samll Cell Lung Cancer Treatment For Individual Basic And Clinical Research

Objective: RRM1 and ERCC-1 was tested for non-small cell lung cancer with Immunohistochemistry S-P ,analyzed its relationship with clinical pathological factors ,survival time and chemotherapeutic effect,to provide the relable basis for individual chemotherapy in NSCLC.Methods: The expression of ERCC-1 and RRM1 in 60 advancecd NSCLC patients who were treated by NP, GP plan independent chemotherapy was tested with Immunohistochemistry S-P .SPSS(13.0) statistical software was applied for data analysis. The correlation between the expression of ERCC-1 and RRM1 and the major clincal pathological characteristics of NSCLC were analyzed by Chi-square test .Postoperative survival period analysis were Computed by the Kaplan-Meier method and computed by the Log-Tank test.,test levelα= 0.05.Results 1. The positive expression of ERCC-1 and RRM1 separately were 53.3% and 60%.2.The expression of ERCC-1 is no statistically significant difference in sex,age,pathological type (P>0.05).3 The expression of RRM1 is no statistically significant difference in sex,age,pathological type (P>0.05).4. The efficiency of chemotherapy was 25% in ERCC-1 positive group, The efficiency of chemotherapy was 57.1% in ERCC-1 negative group, having stactistically significant difference (p=0.023). the average survival time of positive group and negative group separately were 7.7 months and 13.1 months(p=0.005).;1-year survival rates of positive group and negative group separately were 21.9% and 60.1%(p=0.004); both being significant difference(p<0.05). 5 the efficiency of chemotherapyd is 30% in RRM1 positive group,the efficiency of chemotherapyd is 50% in RRM1 negative group,not having significant difference (p=0.197), the average survival time of Positive group and negative group separatelywere 7.8 months, 9.1 months, there was no significant difference (P = 0.783), 1-year survival of positive group and negative group ratesseparately were 38.9%, 41.7%, not having significant difference (p=0.783).6 the chemotherapy efficiency of NP and GP separately were 47.6% and 13.3% in 36 RRM1 positive group , being significant difference (p=0.04). average survival period of NP and GP separately were 8.9 months,5.3 months (p=0.019);1-year survival rates NP and GP separately were 42.9%,20% (p=0.025), both having significant difference(p < 0.05).7 the chemotherapy efficiency of NP and GP separately were 44.4% and53.3% in 24 RRM1 negative group , not having significant difference (p=0.343). average survival period of NP and GP separately were 9.8 months,11.6 months (p=0.186); 1-year survival rates NP and GP separately were 30%,46.7% (p=0.478);both having not significant difference(p>0.05). 8 there are positive relativity between the expression level of RRM1 and ERCC-1 in NSCLC(r=0.359,P=0.045).Conclusion 1. ERCC-1expression is no statistically significant difference in sex, age, pathological type 2.RRM1 expression is no statistically significant difference in sex, age, pathological type 3.there are relativity in the expression of ERCC-1 in NSCLC and platium-bsed chemotherapy drugs , the chemotherapeutic effect is bad in positive expression 4.there are relativity in the expression of RRM1 in NSCLC and GP ,the chemotherapeutic effect is bad in positive expression 5.According to the expression of ERCC-1,RRM1 to choose chemotherapy programs ,improve chemotherapeutic effect and extended survival time of patients...